Skip to main content

Beneficial ownership — 13D / 13G

87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
Millennium Management LLC UTZ Utz Brands, Inc. 13G 5.1% 2y
Heilbron Jack Kendrick SQFT Presidio Property Trust, Inc. 13D/A 8.2% 2y
Southpoint Capital Advisors LP MBLY Mobileye Global Inc. 13G 5% 2y
RA CAPITAL MANAGEMENT, L.P. SERA Sera Prognostics, Inc. 13G 6.5% 2y
STEADFAST CAPITAL MANAGEMENT LP SPR Spirit Aerosystems Holdings, Inc. 13G 5.5% 2y
Estate of Daniel L. Goodwin BY Byline Bancorp, Inc. 13G 9.6% 2y
RS Fund LP NURO NeuroMetrix, Inc. Common Stock 13D/A 9.9% 2y
Artal Participations S.a r.l VIGL Vigil Neuroscience, Inc. Common Stock 13G/A 4.9% 2y
Bain Capital Life Sciences Fund II, L.P. NUVL Nuvalent, Inc. 13D/A 4.1% 2y
Samsara BioCapital, L.P. NKTX Nkarta, Inc. 13D/A 5.4% 2y
Leviticus Partners LP ORN Orion Group Holdings Inc 13G/A 4.17% 2y
CAS Investment Partners, LLC CDLX Cardlytics, Inc. 13D/A 14.4% 2y
James N. Topper PBYI Puma Biotechnology, Inc. 13G 5.4% 2y
Carlyle Group Inc. QTTB Q32 Bio Inc. 13G 9.2% 2y
STEPHEN FITZPATRICK EVTL Vertical Aerospace Ltd. 13D 75.53% 2y
HCM Investor Holdings, LLC MRNO Murano Global Investments Plc 13D 11% 2y
RA CAPITAL MANAGEMENT, L.P. ANRO Alto Neuroscience, Inc. 13G 5.2% 2y
Lynx1 Capital Management LP PASG Passage BIO, Inc. 13G 8.7% 2y
John Cotterell DAVA Endava plc 13G/A 15.1% 2y
BAKER BROS. ADVISORS LP IGMS IGM Biosciences, Inc. Common Stock 13D/A 12.4% 2y
SIT INVESTMENT ASSOCIATES INC VPV Invesco Pennsylvania Value Municipal Income Trust 13D 9.9% 2y
SIT INVESTMENT ASSOCIATES INC KTF Dws Municipal Income Trust 13D/A 14.59% 2y
SIT INVESTMENT ASSOCIATES INC VTN Invesco Trust for Investment Grade New York Municipals 13D 8.28% 2y
Antofagasta plc BVN Buenaventura Mining Co Inc 13D/A 18.9% 2y
New Enterprise Associates 15, L.P. NKTX Nkarta, Inc. 13D/A 5.1% 2y
Venu Raman Kumar AERT Aeries Technology, Inc. 13D/A 73.8% 2y
NOVO HOLDINGS A/S SPRB Spruce Biosciences, Inc. 13D/A 3.9% 2y
PW Partners Atlas Fund IV LP BJRI BJs RESTAURANTS INC 13D/A 5.4% 2y
Bhisham Khare AERT Aeries Technology, Inc. 13D 9.83% 2y
LUO Jie UXIN Uxin Ltd 13D 1.9% 2y
Michael Rapoport HYFM Hydrofarm Holdings Group, Inc. 13G 5.1% 2y
Eve One Fund II L.P. UXIN Uxin Ltd 13D/A 62.1% 2y
Timothy A. Springer RNAC Cartesian Therapeutics, Inc. 13D/A 27.9% 2y
ORBIMED ADVISORS LLC QTTB Q32 Bio Inc. 13D 18.9% 2y
Joy Capital Opportunity, L.P. UXIN Uxin Ltd 13D/A 31.1% 2y
GSK plc NKTX Nkarta, Inc. 13D/A 4.5% 2y
Radoff Bradley Louis SPRB Spruce Biosciences, Inc. 13G 6.9% 2y
Alpha Wave Global, LP LENZ LENZ Therapeutics, Inc. 13G 14.1% 2y
Elías Sacal Cababié MRNO Murano Global Investments Plc 13D 87.2% 2y
Velan Capital Investment Management LP OTLK Outlook Therapeutics, Inc. 13G 5.6% 2y
TANG CAPITAL MANAGEMENT, LLC OTLK Outlook Therapeutics, Inc. 13G 9.99% 2y
BIGLARI CAPITAL CORP. BH-A Biglari Holdings Inc. 13D/A 71.5% 2y
TLCW VENTURES PTE.LTD WBUY Webuy Global Ltd 13G 11.98% 2y
AyurMaya Capital Management Company, LP SLRN ACELYRIN, INC. Common Stock 13G 9.6% 2y
Vincent K. McMahon TKO TKO Group Holdings, Inc. 13G 24.7% 2y
Omni Retail Enterprises, LLC 1 WHLM Wilhelmina International, Inc. 13G 18.4% 2y
Impact Prosperity Partners, LLC, as Agent 1 WHLM Wilhelmina International, Inc. 13G/A 0% 2y
Harraden Circle Investments, LLC PFSA Profusa, Inc. 13G 5.04% 2y
Thomas J. Herzfeld, et al. HERZ Herzfeld Credit Income Fund, Inc 13D/A 26.03% 2y
Fairmount Funds Management LLC COGT Cogent Biosciences, Inc. 13D/A 9.9% 2y